Clinical Trial TitleStudy of ATH-1017 for the Treatment of Alzheimer's Disease
National Clinical Trial Number:NCT04488419
Clinical Trial Protocol Description:
The purpose of the study is to test if an experimental drug called ATH-1017 is safe and helpful to people with memory and thinking problems associated with Alzheimer's Disease. The study treatments, ATH-1017 or a placebo, will be assigned randomly. Nationwide, 300 participants will be recruited for this study. At Rush University Medical Center, we expect to recruit up to 15 participants.
Clinical Trial Eligibility Criteria:
In order to participate, you must:
- Be 55-85 years old.
- Have a diagnosis of mild to moderate Alzheimer's Disease.
- Have an individual who knows you well willing to take part in the study with you as your study partner.
You will be excluded from the study if you:
- Are unable or unwilling to complete all study activities.
- Have other medical conditions, illnesses or diseases that could interfere with study participation.
This is a partial list of inclusion and exclusion criteria.